OBJECTIVE: This study updated a 2001 decision economic model that used indirect data and confirmed its findings by developing a new cost-effectiveness model by using now available head-to-head data. The models compared @entity1037 with @entity1280 in the treatment of @entity161 in the United States. METHODS: A decision analytic modeling approach was used to estimate annual health-care costs and health outcomes, incorporating events such as response, relapse, and suicide. @entity1 without response to first-line treatment switched to the other comparator. Decision tree probabilities were extracted from head-to-head studies and other published clinical literature. Direct health-care costs and quality-adjusted life-years (QALYs) were estimated on the basis of resource use and utility weights for initial and relapse episodes, maintenance therapy, and extended episodes of illness. Disutilities associated with treatment-emergent adverse events were included. RESULTS: Consistent with the 2001 model, this model found that first-line treatment with @entity1037 is associated with fewer hospital days, fewer days with @entity21 , and higher QALYs than is first-line treatment with @entity1280 . Total costs were lower for the @entity1037 pathway ( 70,232- 72,776 vs.  73,086- 73,310 in the Positive and Negative Syndrome Scale analysis) due to the cost savings associated with reduced health-care resource use. The incremental cost per QALY gained indicated that the @entity1037 pathway dominated the @entity1280 pathway. CONCLUSIONS: Decision analytic models should be continuously assessed against new data. This case study shows that incorporating new data confirmed results of a previously published model in which @entity1037 was associated with better expected health outcomes and lower total health-care costs than was @entity1280 .

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity1280 :: ('MESH:C092292', 'Chemical') :: ['ziprasidone'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
